Clinical trials: Cerebrovascular Disorders
Atherosclerosis
A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis
The purpose of this study is to evaluate the safety and efficacy of K-604 for the treatment of atherosclerosis.
- Trial name
- NCT00851500
- Testing
- K-604
- Where
- 19 sites in United States
- Volunteers
- 210 people
- Sponsor
- Kowa Research Institute, Inc.
Fabry Disease
A Study of Replagal in Treatment-naïve Adults With Fabry Disease
In this study, adults with Fabry Disease who have not had any treatment for this condition will be treated with Replagal. The main aim of the study is to check if Replagal improves kidney function and heart structure of…
- Trial name
- NCT04840667
- Testing
- REPLAGAL
- Where
- 28 sites in Canada, Finland and 6 more
- Volunteers
- 17 people
- Sponsor
- Shire
Vascular Dementia
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
This clinical trial was performed to assess the clinical efficacy and safety of two 4 week treatment courses of daily intravenous administration of Cerebrolysin (20mL [milliliter] IV [intravenous] per day).
- Trial name
- VascDem (NCT00947531)
- Testing
- Cerebrolysin, 0.9% Saline Solution
- Where
- 21 sites in Russia
- Volunteers
- 242 people
- Sponsor
- Ever Neuro Pharma GmbH
Intracerebral Hematoma
Stereotactic, Robot-assisted Intracerebral Hemorrhage Clot Evacuation
Non-traumatic intracerebral hemorrhage (ICH) affects approximately 100,000 Americans yearly. Up to 30-50% of ICH is fatal, and those patients who survive are often left with significant neurologic dysfunction.
- Trial name
- NCT03414307
- Testing
- Intracerebral catheter placement, Robot-assisted intracerebral catheter
- Where
- United States
- Sponsor
- Zimmer Biomet
Intracranial Arteriosclerosis
A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）
The trial is a prospective, multicenter, open-label, superiority, randomized controlled clinical trial. The experimental groups include two types of drug-eluting stents: Experimental Device A, a self-expanding rapamycin…
- Trial name
- NCT06925971
- Testing
- Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China), Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China), Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China),
- Where
- China
- Volunteers
- 279 people
- Sponsor
- MicroPort NeuroTech Co., Ltd.
Brain Aneurysms
International Retrospective Study of Pipeline Embolization Device
The primary objective of this retrospective study is to determine the incidence of important safety outcomes in patients who have undergone Pipeline Embolization Device placement for intracranial aneurysms (IAs).
- Trial name
- IntrePED (NCT01558102)
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 793 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Carotid Stenosis, Constriction, Pathologic
GORE Flow Reversal System and GORE Embolic Filter Extension Study
The objective of this study is to provide an ongoing evaluation of clinical outcomes associated with the GORE Flow Reversal System and the GORE Embolic Filter when used for embolic protection during carotid artery stenting.
- Conditions
- Carotid Stenosis, Constriction, Pathologic, Carotid Artery Diseases, Cerebrovascular Disorders
- Trial name
- FREEDOM (NCT01343667)
- Testing
- Gore Flow Reversal System, Gore Embolic Filter
- Where
- 39 sites in United States
- Volunteers
- 1,397 people
- Sponsor
- W.L.Gore & Associates
Fabry Disease, Alpha Galactosidase A Deficiency
Study of the Effects of Fabrazyme Treatment on Lactation and Infants
The study was planned for up to 2 years (24 months). Planned full participation for both mother and infant was 24 months, planned full participation of mother and development of infant was 24 months, while planned full…
- Trial name
- NCT00230607
- Testing
- agalsidase beta
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 7 people
- Sponsor
- Genzyme, a Sanofi Company
Stroke
Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke
The main objective of this study is to assess the safety and effectiveness of the ReVive SE (Self- Expanding) Neurothrombectomy Device in subjects requiring mechanical thrombectomy when used according to its Instruction for use…
- Trial name
- Re-ACT (NCT02169492)
- Where
- 8 sites in France
- Volunteers
- 103 people
- Sponsor
- Codman & Shurtleff
Cardiovascular Diseases, Atrial Fibrillation
A Digital Flu Intervention for People With Cardiovascular Conditions
A 6-month prospective, digital randomized controlled trial targeting approximately 49,000 individuals to evaluate the effectiveness of an influenza vaccination intervention during influenza season for people with cardiovascular…
- Conditions
- Cardiovascular Diseases, Atrial Fibrillation, Abnormal Heart Rhythms, Cardiac Arrest
- Trial name
- CardioFlu (NCT04584645)
- Testing
- Targeted digital intervention
- Where
- United States
- Volunteers
- 49,138 people
- Sponsor
- Evidation Health
Stroke
Validation of Sensitivity and Specificity of a Multi-Omic Precision Diagnostic for Acute Stroke Evaluation
Valtari Bio has early proof of concept clinical data of a multi-omic peripheral blood biomarker profile that can be used to determine stroke from no stroke in the emergency setting.
- Trial name
- VALISS (NCT02753257)
- Testing
- Non-Interventional
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Valtari Bio
Acute Ischemic Stroke
Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke
This is a randomized, placebo-controlled, phase 3 clinical trial to evaluate the efficacy and safety of transcranial ultrasound (US) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute…
- Trial name
- CLOTBUST-ER (NCT01098981)
- Testing
- Transcranial ultrasound as an adjunctive therapy to tPA, Standard of care tPA therapy for acute ischemic stroke
- Where
- United States
- Volunteers
- 675 people
- Sponsor
- Cerevast Therapeutics, Inc.
Birth Asphyxia
Asphyxia Associated Metabolite Biomarker Investigation 2
Follow-up of participants of AAMBI1 study at age of at least 2 years. AAMBI1(ClinicalTrials.gov ID: NCT03354208): Verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia.
- Trial name
- AAMBI2 (NCT04714502)
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 144 people
- Sponsor
- InfanDx AG
Intracranial Aneurysm
FRED Retrospective Study of Intracranial Aneurysms Treatment
To evaluate the long-term safety and efficacy of Flow Re-Direction Endoluminal Device System (FRED) in the treatment of intracranial aneurysms in the post-market environment
- Trial name
- FRED (NCT06982781)
- Testing
- Flow Re-Direction Endoluminal Device System(FRED)
- Volunteers
- 2,000 people
- Sponsor
- Microvention-Terumo, Inc.
Intraventricular Hemorrhage, Subarachnoid Hemorrhage
The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of Intraventricular Hemorrhage (IVH)
The primary goal of this study is to assess the occurrence of flushing interventions to address occlusions during the treatment of interventricular hemorrhage (spontaneous primary IVH or secondary IVH due to ruptured aneurysm).
- Trial name
- NCT05113381
- Testing
- CerebroFlo™ EVD Catheter
- Where
- 10 sites in United States
- Volunteers
- 105 people
- Sponsor
- Integra LifeSciences Corporation
Microscopic Polyangiitis (MPA), Granulomatosis With Polyangiitis (GPA)
Special Drug Use-results Survey for Long-term Use（Avacopan）
The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.
- Trial name
- NCT06758271
- Testing
- Avacopan
- Where
- Japan
- Volunteers
- 250 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
ALS (Amyotrophic Lateral Sclerosis), TBI Traumatic Brain Injury
Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro
The goal of this study is refine the usability of a BCI capable communication platform. The study will take place in the United States area and will enroll up to 10 participants with late stage ALS, traumatic brain injury (TBI)…
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), TBI Traumatic Brain Injury, SCI - Spinal Cord Injury, Stroke
- Trial name
- NCT07209943
- Testing
- Cognixion + Apple Vision Pro
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cognixion
Intracranial Arterial Diseases, Stent Restenosis
The Efficacy and Safety of Intracranial Self-expanding DES in Symptomatic Intracranial Atherosclerotic Disease
The primary objective of this trial is to evaluate the safety and efficacy of SINOMED IS- DES in patients with symptomatic intracranial atherosclerotic stenosis.
- Conditions
- Intracranial Arterial Diseases, Stent Restenosis, Percutaneous Transluminal Angioplasty
- Trial name
- NCT05217459
- Testing
- Self-expanding intracranial drug stent system
- Where
- 14 sites in China
- Volunteers
- 128 people
- Sponsor
- Sinomed Neurovita Technology Inc.
Vascular Dementia
The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD).
- Trial name
- NCT03789760
- Testing
- SaiLuoTong capsule
- Where
- 29 sites in China
- Volunteers
- 493 people
- Sponsor
- Shineway Pharmaceutical Co.,Ltd
Acute Ischemic Stroke
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study.
- Trial name
- ACTISAVE (NCT05070260)
- Testing
- Intravenous glenzocimab (ACT017) 1000 mg
- Where
- 10 sites in United States, Germany
- Volunteers
- 438 people
- Sponsor
- Acticor Biotech